Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ARGX · against 57 other Healthcare companies of similar size
Ranked #52 of 58 · scores higher than 11% of peers
Bars: peers in each 10-point band of the valuation score9 peers with a valuation score of 40–49, including ARGX · Click a bar to see the companies
A mix: stronger earnings yield, but weaker EBITDA yield than most Healthcare peers.
| Metric | ARGX | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 55 reported | 3.2% | 2.9% | 57% | 30% | |
| EBITDA yieldHigher is better · 59 reported | 0.1% | 6.1% | 5% | 50% | |
| Free cash flow yieldHigher is better · 42 reported | Not reported | 3.7% | — | — | 20% |
| Book yieldHigher is better · 54 reported | 0.6% | 21.1% | 6% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 4.61T JPY (≈$31.3B) | 93 | 76 | |
| 2 | 78.1B USD | 89 | 60 | |
| 3 | 108.6B USD | 88 | 66 | |
| 4 | 97.5B USD | 87 | 67 | |
| 5 | 6.17T JPY (≈$42.0B) | 86 | 70 | |
| 47 | 54.9B USD | 47 | 59 | |
| 49 | 40.2B USD | 46 | 73 | |
| 49 | 49.1B USD | 46 | 69 | |
| 51 | 66.3B USD | 44 | 30 | |
| 52 | 56.7B USD | 42 | 79 | |
| 53 | 2.67T INR (≈$32.1B) | 39 | 68 | |
| 54 | 45.2B USD | 38 | 46 | |
| 55 | 33.3B USD | 8 | 24 | |
| 55 | 91.2B USD | 8 | 18 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score